Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays In Vitro and In Vivo

Abstract

The complement activation peptide C5a is a key mediator of inflammation that is associated with numerous immune disorders. C5a binds and activates two seven-transmembrane receptors, C5aR1 and C5aR2. Experimentally, C5a is utilized to investigate C5a receptor biology and to screen for potential C5aR1/C5aR2 therapeutics. Currently, laboratory sources of C5a stem from either isolation of endogenous C5a from human serum or most predominantly via recombinant expression. An alternative approach to C5a production is chemical synthesis, which has several advantages, including the ability to introduce non-natural amino acids and site-specific modifications whilst also maintaining a lower probability of C5a being contaminated with microbial molecules or other endogenous proteins. Here, we describe the efficient synthesis of both human (hC5a) and mouse C5a (mC5a) without the need for ligation chemistry. We validate the synthetic peptides by comparing pERK1/2 signaling in CHO-hC5aR1 cells and primary human macrophages (for hC5a) and in RAW264.7 cells (for mC5a). C5aR2 activation was confirmed by measuring β-arrestin recruitment in C5aR2-transfected HEK293 cells. We also demonstrate the functionalization of synthetic C5a through the introduction of a lanthanide chelating cage to facilitate a screen for the binding of ligands to C5aR1. Finally, we verify that the synthetic ligands are functionally similar to recombinant or native C5a by assessing hC5a-induced neutrophil chemotaxis in vitro and mC5a-mediated neutrophil mobilization in vivo. We propose that the synthetic hC5a and mC5a described herein are valuable alternatives to recombinant or purified C5a for in vitro and in vivo applications and add to the growing complement reagent toolbox.

TLQP-21 is a low potency partial C3aR activator on human primary macrophages

“…Human C5a, human TLQP-21 (TLQPPSALRRRHYHHALPPSR) and mouse TLQP-21 (TLQPPASSRRRHFHHALPPAR) were synthesized by Fmoc-based solid phase peptide synthesis using previously described methods ( 18 , 19 ). The C3aR inhibitor, SB290157 trifluoroacetate salt, and purified human C3a were purchased from Merck (Perth, Australia).…”

Protocol for cell-based screening assay to measure ERK1/2 phosphorylation as a readout for complement receptor activation

“…The details can be found in our prior publications. 1 , 2 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 Based on our work, we recommend the following ligand concentrations and treatment schemes in CHO cell lines ( Table 1 ). Any hits can then be progressed for validation in HMDMs.…”